Sponsored Videos

Logan Melchione shares how ClaimGuardRx gives account teams a fast, conversational way to tackle diversion and fraud together, and what that means for clients and patients.

Bryan Dennison breaks down the purpose-built technology behind ClaimGuardRx and how its detect-and-respond design keeps manufacturers ahead of evolving diversion tactics.

Matt Turner shares how ClaimGuardRx is redefining patient affordability by turning claims data into a proactive defense against maximizers and accumulators.

Bansi Nagji discusses the shifting science behind rare and orphan drug development, including what it takes for therapies to succeed well beyond launch.

As health technology assessments (HTA) requirements evolve and joint clinical assessments (JCA) reshape Europe, pharma companies face growing pressure to align evidence, access, and strategy earlier in development cycles.

Supply chain data across stationary and in-transit monitoring can accelerate product release and reduce waste for pharma companies.

Hear from Miranda Delatore, CoverMyMeds, on how a connected specialty access and affordability ecosystem is eliminating delays, reducing friction, and transforming the way biopharma manufacturers get patients started on life-changing therapies faster than ever before.

Streamlined hub services, clinical navigators, and data-driven field reimbursement are transforming the rare disease patient journey.

Learn how to navigate growing complexity, reduce workflow fragmentation, and design access and affordability programs that support patients throughout their treatment journey.

Biopharma manufacturers are navigating growing supply chain complexities, including increased demand for cold chain capacity, the need for sustainable shipping solutions, and the pressure to move products from FDA approval to patients as quickly as possible.

Krystal Haynes, Senior Director of Business Development, ICS, at Cencora, outlines the challenges facing cell and gene therapy manufacturers as they attempt to move products from clinical development to commercial availability.

Building effective pharmaceutical supply chain partnerships requires intentional investment in communication, internal alignment, and structured governance to navigate an increasingly volatile industry landscape.

Sydni Johnston, Associate Director at Cardinal Health Sonexus™ Access and Patient Support, explains how manufacturers can build more stable and scalable patient support programs by adopting a flexible approach that aligns hub models with specific organizational goals.

Cindy Baksh, ConnectiveRx, discusses pharma's shift from reactive audits to real-time prevention—protecting billions in copay spend while ensuring support reaches the patients who need it most.

Chris Dowd and Lisa Prowker of ConnectiveRx discuss point-of-care marketing as the key activation layer for investments in patient access and support—it’s essential for converting dollars spent in payer negotiations and copay programs into prescriptions.

Valerie Bandy and Ryan Rotar, both from Tecsys, examine how hospital pharmacy leaders are reshaping their expectations and prioritizing value-driven partnerships over traditional transactional vendor relationships. They explore the growing shift toward self-distribution and direct purchasing, as well as how transparency and proactive communication are now essential to mitigating logistics risk and safeguarding patient care. This interview stresses technology’s role as a critical enabler of data visibility, empowering manufacturers to build long-term trust through consistent performance and shared accountability.

Discover how AI-powered patient intelligence is ushering in a new era of pharma leadership defined by clarity, speed, and knowing the “why” behind every shift.

Understand how real-time patient intelligence transforms leadership conversations from speculation and opinion battles into confident, data-backed strategy.

Learn how outdated or incomplete insights turn every decision into a high-stakes gamble that cost brands money, momentum, and internal alignment.

David Edelman, Founder & CEO of Thrivable, provides an unflinching look at why today’s most relied-upon tools, including syndicated data, social listening, gut instinct, still leave leaders navigating with a blurry, incomplete map.

This episode acts as a peek inside the modern pharma boardroom, where leaders are expected to defend billion-dollar brands with data that’s too slow, too vague, and too outdated to survive today’s market velocity.

This series kicks off by introducing David Edelman, Founder & CEO of Thrivable, who joins Pharmaceutical Executive to discuss the rising “clarity gap” that is currently putting pharma leaders under pressure.

Discover how agentic AI is reshaping life sciences commercial operations.

A panel of industry leaders share key insights supporting the integration of patient-centric strategies into current and future drug development and market access efforts.

Industry stakeholders suggest how pharmaceutical companies can proactively plan for the potential implementation of a Most Favored Nation (MFN) pricing model.

Industry experts react to the developer’s role in preparing for value-based contracting, acknowledging that innovative agreements can support access when evidence is still maturing.

A panel of key opinion leaders consider how payers and manufacturers are increasingly embracing innovative contracting models that require strong value propositions, strategic planning, and significant upfront investment in data and stakeholder alignment.

Edward Ahn, CEO of MEDIPOST, Inc., reacts to the challenge of launching orphan drugs without complete evidence, particularly given their high cost and limited patient populations, and suggests strategies that can be used to address evidence gaps, enable market access, and support long-term patient benefit.